Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-01-07

AUTHORS

Reeti Joshi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Yujin Park, Prashanth Sunkureddi

ABSTRACT

ObjectivesTo characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.MethodsThis descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected.ResultsMedical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic naïve. The most common reasons for secukinumab initiation among biologic-naïve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150 mg every week (39.7%), 300 mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received ≥ 1 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150 mg and 300 mg, respectively, every 4 weeks.ConclusionsIn this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic naïve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab. More... »

PAGES

1-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9

DOI

http://dx.doi.org/10.1007/s40801-018-0146-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111241892

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30617811


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Baylor College of Medicine, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joshi", 
        "givenName": "Reeti", 
        "id": "sg:person.014176477447.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014176477447.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Montreal, QC, Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Analysis Group, Inc., Montreal, QC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Latremouille-Viau", 
        "givenName": "Dominick", 
        "id": "sg:person.01245200117.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245200117.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417986.5", 
          "name": [
            "Analysis Group, Inc., Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meiselbach", 
        "givenName": "Mark K.", 
        "id": "sg:person.015345301707.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015345301707.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group, Inc., Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Analysis Group, Inc., Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Jipan", 
        "id": "sg:person.01151424673.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Yujin", 
        "id": "sg:person.01176534524.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176534524.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Texas Medical Branch, Galveston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.176731.5", 
          "name": [
            "University of Texas Medical Branch, Galveston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sunkureddi", 
        "givenName": "Prashanth", 
        "id": "sg:person.0655601370.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655601370.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13075-017-1490-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922896", 
          "https://doi.org/10.1186/s13075-017-1490-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-018-4112-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103626320", 
          "https://doi.org/10.1007/s10067-018-4112-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-016-0969-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042895881", 
          "https://doi.org/10.1186/s13075-016-0969-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-015-2958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052577864", 
          "https://doi.org/10.1007/s10067-015-2958-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-016-3231-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022348277", 
          "https://doi.org/10.1007/s10067-016-3231-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01-07", 
    "datePublishedReg": "2019-01-07", 
    "description": "ObjectivesTo characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.MethodsThis descriptive analysis of data from a US retrospective medical chart review included patients aged\u2009\u2265\u200918\u00a0years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected.ResultsMedical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic na\u00efve. The most common reasons for secukinumab initiation among biologic-na\u00efve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150\u00a0mg every week (39.7%), 300\u00a0mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received\u2009\u2265\u20091 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150\u00a0mg and 300\u00a0mg, respectively, every 4\u00a0weeks.ConclusionsIn this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic na\u00efve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0146-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "medical chart review", 
      "retrospective medical chart review", 
      "chart review", 
      "efficacy/effectiveness", 
      "biologic na\u00efve", 
      "common reason", 
      "physician-level characteristics", 
      "biologic-experienced patients", 
      "co-morbidity profile", 
      "biologic-na\u00efve", 
      "characterization of patients", 
      "prior biologics", 
      "secukinumab dose", 
      "index date", 
      "patient demographics", 
      "medical charts", 
      "loading dose", 
      "US patients", 
      "mean age", 
      "disease characteristics", 
      "secukinumab", 
      "physician survey", 
      "patients", 
      "clinical practice", 
      "treatment history", 
      "one-third", 
      "weeks", 
      "spondylitis", 
      "rheumatologists", 
      "dose", 
      "biologics", 
      "na\u00efve", 
      "treatment", 
      "prescription", 
      "descriptive analysis", 
      "review", 
      "failure", 
      "years", 
      "dosing", 
      "ObjectivesTo", 
      "ConclusionsIn", 
      "charts", 
      "demographics", 
      "AS", 
      "age", 
      "date", 
      "initiation", 
      "reasons", 
      "history", 
      "effectiveness", 
      "survey", 
      "profile", 
      "practice", 
      "characteristics", 
      "data", 
      "online forms", 
      "analysis", 
      "information", 
      "form", 
      "characterization", 
      "rheumatologist-reported reasons", 
      "MethodsThis descriptive analysis", 
      "US retrospective medical chart review", 
      "Eligible rheumatologists", 
      "first secukinumab prescription", 
      "secukinumab prescription", 
      "ResultsMedical charts", 
      "secukinumab initiation", 
      "maintenance secukinumab dose", 
      "US medical chart review", 
      "secukinumab efficacy/effectiveness", 
      "US Physician Survey"
    ], 
    "name": "Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review", 
    "pagination": "1-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111241892"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0146-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30617811"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0146-9", 
      "https://app.dimensions.ai/details/publication/pub.1111241892"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_824.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0146-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0146-9'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      22 PREDICATES      103 URIs      90 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0146-9 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Na9a6e797a51f45d2a43a2e2ee0a91c28
4 schema:citation sg:pub.10.1007/s10067-015-2958-2
5 sg:pub.10.1007/s10067-016-3231-z
6 sg:pub.10.1007/s10067-018-4112-4
7 sg:pub.10.1186/s13075-016-0969-2
8 sg:pub.10.1186/s13075-017-1490-y
9 schema:datePublished 2019-01-07
10 schema:datePublishedReg 2019-01-07
11 schema:description ObjectivesTo characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.MethodsThis descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Information on physician-level characteristics and reasons for secukinumab prescription and dosing were also collected.ResultsMedical charts from 78 patients with AS who initiated secukinumab were reviewed by 25 rheumatologists between 7 July 2017 and 11 August 2017. Overall, 76.9% of patients were male, mean (SD) age was 39.8 (10.8) years, and 34.6% were biologic naïve. The most common reasons for secukinumab initiation among biologic-naïve and biologic-experienced patients, respectively, were efficacy/effectiveness (77.8%) and failure of other prior biologics (84.3%). Nearly all patients (94.9%) received a loading dose, including 150 mg every week (39.7%), 300 mg every week (53.8%), and other (1.3%). Overall, 73 patients (93.6%) received ≥ 1 maintenance secukinumab dose, of whom 56.2% and 43.8% received 150 mg and 300 mg, respectively, every 4 weeks.ConclusionsIn this US medical chart review of patients with AS who initiated secukinumab, approximately one-third were biologic naïve, and secukinumab efficacy/effectiveness and failure of other biologics were the most common reasons for initiating secukinumab.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree true
15 schema:isPartOf N3fdcf4424ec1432bb9f5cbba8802ebf7
16 Nc80bff4c34e844bbb0e0c89283248710
17 sg:journal.1051855
18 schema:keywords AS
19 ConclusionsIn
20 Eligible rheumatologists
21 MethodsThis descriptive analysis
22 ObjectivesTo
23 ResultsMedical charts
24 US Physician Survey
25 US medical chart review
26 US patients
27 US retrospective medical chart review
28 age
29 analysis
30 biologic naïve
31 biologic-experienced patients
32 biologic-naïve
33 biologics
34 characteristics
35 characterization
36 characterization of patients
37 chart review
38 charts
39 clinical practice
40 co-morbidity profile
41 common reason
42 data
43 date
44 demographics
45 descriptive analysis
46 disease characteristics
47 dose
48 dosing
49 effectiveness
50 efficacy/effectiveness
51 failure
52 first secukinumab prescription
53 form
54 history
55 index date
56 information
57 initiation
58 loading dose
59 maintenance secukinumab dose
60 mean age
61 medical chart review
62 medical charts
63 naïve
64 one-third
65 online forms
66 patient demographics
67 patients
68 physician survey
69 physician-level characteristics
70 practice
71 prescription
72 prior biologics
73 profile
74 reasons
75 retrospective medical chart review
76 review
77 rheumatologist-reported reasons
78 rheumatologists
79 secukinumab
80 secukinumab dose
81 secukinumab efficacy/effectiveness
82 secukinumab initiation
83 secukinumab prescription
84 spondylitis
85 survey
86 treatment
87 treatment history
88 weeks
89 years
90 schema:name Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
91 schema:pagination 1-9
92 schema:productId N7a40238d372a47fd881e9ca805a4c37b
93 N937e121c1fc24a69935ecbf2a3449048
94 N9a57396e797d473586e2748a3f5abc68
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111241892
96 https://doi.org/10.1007/s40801-018-0146-9
97 schema:sdDatePublished 2021-11-01T18:36
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Nc34f9b7d029e49269a3d10ffddb9a48b
100 schema:url https://doi.org/10.1007/s40801-018-0146-9
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N3fdcf4424ec1432bb9f5cbba8802ebf7 schema:volumeNumber 6
105 rdf:type schema:PublicationVolume
106 N7a40238d372a47fd881e9ca805a4c37b schema:name doi
107 schema:value 10.1007/s40801-018-0146-9
108 rdf:type schema:PropertyValue
109 N7ec86f62225746b687a37a3a7c9062c2 rdf:first sg:person.015345301707.41
110 rdf:rest Nef945e2a9a0046e0adcf5a7cabfcdcc9
111 N8bc99ffc2d004dedab944754e4ef5c0e rdf:first sg:person.01245200117.73
112 rdf:rest N7ec86f62225746b687a37a3a7c9062c2
113 N937e121c1fc24a69935ecbf2a3449048 schema:name dimensions_id
114 schema:value pub.1111241892
115 rdf:type schema:PropertyValue
116 N9a57396e797d473586e2748a3f5abc68 schema:name pubmed_id
117 schema:value 30617811
118 rdf:type schema:PropertyValue
119 Na9a6e797a51f45d2a43a2e2ee0a91c28 rdf:first sg:person.014176477447.84
120 rdf:rest N8bc99ffc2d004dedab944754e4ef5c0e
121 Nc34f9b7d029e49269a3d10ffddb9a48b schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 Nc80bff4c34e844bbb0e0c89283248710 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 Nd99be4d88a0741648dcedddb4690950f rdf:first sg:person.0655601370.99
126 rdf:rest rdf:nil
127 Nef945e2a9a0046e0adcf5a7cabfcdcc9 rdf:first sg:person.01151424673.71
128 rdf:rest Nfed2b71700e04501a3f533707e8f43dc
129 Nfed2b71700e04501a3f533707e8f43dc rdf:first sg:person.01176534524.25
130 rdf:rest Nd99be4d88a0741648dcedddb4690950f
131 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
132 schema:name Medical and Health Sciences
133 rdf:type schema:DefinedTerm
134 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
135 schema:name Public Health and Health Services
136 rdf:type schema:DefinedTerm
137 sg:journal.1051855 schema:issn 2198-9788
138 2199-1154
139 schema:name Drugs - Real World Outcomes
140 schema:publisher Springer Nature
141 rdf:type schema:Periodical
142 sg:person.01151424673.71 schema:affiliation grid-institutes:None
143 schema:familyName Xie
144 schema:givenName Jipan
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71
146 rdf:type schema:Person
147 sg:person.01176534524.25 schema:affiliation grid-institutes:grid.418424.f
148 schema:familyName Park
149 schema:givenName Yujin
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176534524.25
151 rdf:type schema:Person
152 sg:person.01245200117.73 schema:affiliation grid-institutes:None
153 schema:familyName Latremouille-Viau
154 schema:givenName Dominick
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245200117.73
156 rdf:type schema:Person
157 sg:person.014176477447.84 schema:affiliation grid-institutes:grid.39382.33
158 schema:familyName Joshi
159 schema:givenName Reeti
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014176477447.84
161 rdf:type schema:Person
162 sg:person.015345301707.41 schema:affiliation grid-institutes:grid.417986.5
163 schema:familyName Meiselbach
164 schema:givenName Mark K.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015345301707.41
166 rdf:type schema:Person
167 sg:person.0655601370.99 schema:affiliation grid-institutes:grid.176731.5
168 schema:familyName Sunkureddi
169 schema:givenName Prashanth
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655601370.99
171 rdf:type schema:Person
172 sg:pub.10.1007/s10067-015-2958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052577864
173 https://doi.org/10.1007/s10067-015-2958-2
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/s10067-016-3231-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1022348277
176 https://doi.org/10.1007/s10067-016-3231-z
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/s10067-018-4112-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103626320
179 https://doi.org/10.1007/s10067-018-4112-4
180 rdf:type schema:CreativeWork
181 sg:pub.10.1186/s13075-016-0969-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042895881
182 https://doi.org/10.1186/s13075-016-0969-2
183 rdf:type schema:CreativeWork
184 sg:pub.10.1186/s13075-017-1490-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922896
185 https://doi.org/10.1186/s13075-017-1490-y
186 rdf:type schema:CreativeWork
187 grid-institutes:None schema:alternateName Analysis Group, Inc., Los Angeles, CA, USA
188 Analysis Group, Inc., Montreal, QC, Canada
189 schema:name Analysis Group, Inc., Los Angeles, CA, USA
190 Analysis Group, Inc., Montreal, QC, Canada
191 rdf:type schema:Organization
192 grid-institutes:grid.176731.5 schema:alternateName University of Texas Medical Branch, Galveston, TX, USA
193 schema:name University of Texas Medical Branch, Galveston, TX, USA
194 rdf:type schema:Organization
195 grid-institutes:grid.39382.33 schema:alternateName Baylor College of Medicine, Houston, TX, USA
196 schema:name Baylor College of Medicine, Houston, TX, USA
197 rdf:type schema:Organization
198 grid-institutes:grid.417986.5 schema:alternateName Analysis Group, Inc., Boston, MA, USA
199 schema:name Analysis Group, Inc., Boston, MA, USA
200 rdf:type schema:Organization
201 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
202 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...